CRLComplete Response Letter
Complete Response Letter Fabre-Kramer Pharmaceuticals, Inc. (Nov 2, 2007)
FDA's complete response letter contains source-text evidence related to Clinical efficacy and substantial evidence, Chemistry, manufacturing, and controls, Statistical analysis. Theme counts identify where the letter discusses a topic; they do not replace review of the exact redacted letter.
Issued
US FDA• EXXUA
